Single Case

Acute Cholecystitis with Significantly Elevated Levels of Serum Carbohydrate Antigen 19-9

Shuji Akimoto^{a, d} Masataka Banshodani^b Masahiro Nishihara^a
Junko Nambu^a Yasuo Kawaguchi^a Fumio Shimamoto^c Kiyohiko Dohi^a
Keizo Sugino^a Hideki Ohdan^d

^aDepartment of Surgery, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan;

^bDepartment of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Hiroshima, Japan; ^cDepartment of Pathology, Faculty of Human Culture and Science, Prefectural University of Hiroshima, Hiroshima, Japan; ^dDepartment of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institution of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

Keywords

Acute cholecystitis · Carbohydrate antigen 19-9 · High elevation · Positron emission tomography-computed tomography

Abstract

Serum carbohydrate antigen 19-9 (CA 19-9), a marker of malignant tumors, is generally slightly elevated in benign conditions. We report a case of acute cholecystitis with a significantly elevated level of serum CA 19-9 based on positron emission tomography (PET)-computed tomography (CT) findings. A 65-year-old woman presented with abdominal pain and fever. A CT image revealed an enlarged gallbladder without tumor shadows. The C-reactive protein (CRP) level was elevated to 7.66 mg/dl. Moreover, the serum CA 19-9 level was significantly elevated to 19,392 U/ml. We started antibiotic treatment, because we suspected acute cholecystitis, but still, we could not ignore the possible presence of malignant tumors. After 11 days of antibiotic treatment, serum CRP and CA 19-9 levels decreased to 0.11 mg/dl and 1,049 U/ml, respectively. There was an accumulation of fluorine 18-labeled fluorodeoxyglucose (maximum standardized uptake value, 9.3) without tumor shadows in the

liver, near the gallbladder, on the PET-CT examination. We considered the possibility that the inflammation had spread from the gallbladder to the liver, made a diagnosis of acute cholecystitis, and performed a cholecystectomy 33 days after treatment initiation. The serum CA 19-9 level decreased to 45 U/ml after the surgery. One year after the surgery, the patient was alive, and the serum CA 19-9 level was 34 U/ml. Acute cholecystitis with a significantly high elevation of the serum CA 19-9 level is rare. In such cases, it is important to confirm the change in the serum CA 19-9 level over time after antibiotic treatment and perform imaging studies to distinguish between inflammation and malignancy.

© 2016 The Author(s)
Published by S. Karger AG, Basel

Introduction

Carbohydrate antigen 19-9 (CA 19-9), which was first described by Koprowski et al. [1] in 1979, is produced in the biliary and pancreatic ductal cells. A CA 19-9 level of <37 U/ml is considered normal [2]. Because CA 19-9 can be detected in gastrointestinal and nongastrointestinal cancers [1, 3], especially pancreatic and biliary cancers, it is a useful serum biomarker for these cancers [2].

Serum CA 19-9 levels can be elevated in many benign conditions, including cholangitis, cholestasis, benign obstructive jaundice, liver cirrhosis, hepatitis, liver cyst, liver abscess, polycystic liver disease, bronchitis, congestive heart disease, diverticulitis, Hashimoto's thyroiditis, ovarian cyst, renal cyst, and rheumatoid arthritis [4–7]. However, the elevation of CA 19-9 levels in these conditions is usually mild [2]. In a patient who presented with acute cholecystitis with gallstones, a high level of serum CA 19-9 was reported, but the value was <5,000 U/ml [8].

Fluorine 18-labeled fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) is an effective diagnostic oncologic imaging technique [9]. However, ¹⁸F-FDG PET demonstrates low specificity for the differentiation of malignant tumors from inflammatory lesions [10].

We report a case of acute cholecystitis with a significantly elevated level of serum CA 19-9 with a diagnosis based on PET-computed tomography (CT) findings.

Case Report

A 65-year-old woman was admitted for evaluation of epigastric pain and fever (38.5°C); these symptoms had begun 7 and 4 days, respectively, prior to admission. The laboratory data of the patient during hospitalization were as follows: white blood cell count of 6,100/μl (normal range: 3,400–9,500/μl); C-reactive protein (CRP) level of 7.66 mg/dl (normal range: <0.5 mg/dl); total bilirubin level of 0.5 mg/dl (normal range: 0.2–1.0 mg/dl); direct bilirubin level of 0.1 mg/dl (normal range: <0.4 mg/dl); aspartate aminotransferase level of 19 IU/l (normal range: 8–38 IU/l); alanine aminotransferase level of 18 IU/l (normal range: 4–44 IU/l), and alkaline phosphatase level of 326 IU/l (normal range: 104–338 IU/l). The serum carcinoembryonic antigen (CEA) level was 1.9 ng/ml (normal range: <5.0 ng/ml), while the serum CA 19-9 level was significantly elevated to 19,392 U/ml (normal range: <37 U/ml). Ultrasonography revealed biliary sludge, a gallstone with a 17-mm diameter, and a thickened wall of the gallbladder (fig. 1a). Contrast-enhanced CT revealed the enlargement and thickened wall of the gallbladder with the gallstone in the neck of the gallbladder (fig. 1b–d).

First, we started antibiotic treatment using levofloxacin, because we suspected acute cholecystitis; however, we could not deny the possibility of the presence of malignant tumors. After 11 days of antibiotic treatment, the symptoms disappeared and serum CRP and CA 19-9 levels decreased to 0.11 mg/dl and 1,049 U/ml, respectively. There was an accumulation of ^{18}F -FDG [maximum standardized uptake value (SUV_{max}), 9.3] without tumor shadows in the medial segment of the liver near the fundus of the gallbladder on the ^{18}F -FDG PET-CT examination of the whole body 28 days after antibiotic treatment initiation (fig. 2). We considered the possibility that the inflammation had spread from the fundus of the gallbladder to the medial segment of the liver.

Accordingly, the patient was regarded as having acute cholecystitis with a gallstone. A cholecystectomy was performed 33 days after antibiotic treatment initiation. Surgery revealed that the gallbladder had severely adhered to the omentum and duodenum, and that the gallstone (17 mm) was incarcerated in the neck of the gallbladder. Macroscopically, the gallbladder was edematous and grossly thickened (fig. 3a). On pathological examination (HE), inflammatory cells spread to all layers of the gallbladder wall. However, there were no findings suggesting malignancy (fig. 3b). On immunostaining examination using a CA 19-9 monoclonal antibody, the cytoplasm of the mucosal epithelium was well-stained with CA 19-9 in the gallbladder wall (fig. 3c, d).

The serum CA 19-9 level decreased to 45 U/ml 21 days after the surgery. One year after the surgery, the patient was alive, and her serum CA 19-9 level was 34 U/ml (within the normal range).

Discussion

CA 19-9, a glycosphingolipid of the Lewis blood group, has been used as a serum tumor marker for malignancies of the gastrointestinal tract, especially of the pancreas and biliary tract [2]. When serum CA 19-9 levels are >1,000 U/ml, patients usually have gastrointestinal cancers [2]. However, a previous report showed that only 4.7% of patients with acute cholangitis or cholestasis had a serum CA 19-9 level >1,000 U/ml [11]. CA 19-9 is produced in the biliary and pancreatic ductal cells; however, the mechanisms of CA 19-9 elevation remain unclear [12]. In this case, the serum CA 19-9 level was significantly elevated in spite of acute cholecystitis (19,392 U/ml). We considered the following mechanisms: first, bile flow may be blocked due to cystic duct obstruction by gallstones and biliary sludge. Then, the epithelial cells of the gallbladder wall may be impaired by the blocked bile flow, increased internal pressure of the gallbladder, and inflammatory conditions. Subsequently, production of CA 19-9 in the epithelium of the gallbladder may be increased, and increased CA 19-9 may leak into the blood circulation.

Occasionally, it is very difficult to distinguish between malignant and benign diseases in patients with significantly elevated levels of serum CA 19-9. For these patients, the diagnosis must be evaluated carefully depending on the conditions [11]. In our case, the serum CA 19-9 level decreased after the antibiotic treatment, and the serum CEA level was within a normal range at the onset of the symptoms. We suggest the following methods to distinguish between malignant and benign diseases in patients with significantly elevated levels of serum CA 19-9: confirm the change in serum CA 19-9 and CRP levels over time after antibiotic treatment and perform imaging studies, confirm the serum CEA level at the onset of symptoms, or use operative rapid pathological diagnosis methods to prevent excessive surgeries.

^{18}F -FDG PET is a diagnostic technique using glucose metabolism differences between benign and malignant lesions [9]. ^{18}F -FDG PET-CT is a combination of functional and anatomic imaging and a highly accurate diagnostic examination [13]. However, ^{18}F -FDG accumulates not only in tumor cells but also in inflammatory cells [10]. A previous report demonstrated that delayed ^{18}F -FDG PET was more helpful than early ^{18}F -FDG PET in the evaluation of malignancy [14], and the mean values of early and delayed SUV of ^{18}F -FDG PET in gallbladder carcinoma were 7.35 and 9.30, respectively. In this case, SUV_{max} was 9.3 and was similar to the delayed SUV of the gallbladder carcinoma in the previous report. Therefore, it was difficult to rely solely on imaging studies to distinguish between inflammation and malignancy. However, our report is valuable in that no previous reports presented PET-CT findings of acute cholecystitis with significantly elevated levels of serum CA 19-9.

Conclusion

Acute cholecystitis with a significantly elevated level of serum CA 19-9 (>10,000 U/ml) is rare. In such a case, it is important to confirm the change in serum CA 19-9 level over time after antibiotic treatment and perform imaging studies to distinguish between inflammation and malignancy.

Statement of Ethics

This study was approved by our institutional review board for human investigations and performed according to the principles of the Declaration of Helsinki. Written informed consent for the procedure and publication of this case report and any accompanying images was obtained from the patient.

Disclosure Statement

The authors declare no conflicts of interest or funding interests in connection with the publication of this article. No external funding was used to perform this investigation.

References

- 1 Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. *Somatic Cell Genet* 1979;5:957–971.
- 2 Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. *Am J Gastroenterol* 1990;85:350–355.
- 3 Koprowski H, Herlyn M, Steplewski Z, Sears HF: Specific antigen in serum of patients with colon carcinoma. *Science* 1981;212:53–55.
- 4 Albert MB, Steinberg WM, Henry JP: Elevated serum levels of tumor marker CA19-9 in acute cholangitis. *Dig Dis Sci* 1988;33:1223–1225.
- 5 Turtel PS, Kreel I, Israel J, Frager D, Berman D: Elevated CA 19-9 in a case of Mirizzi's syndrome. *Am J Gastroenterol* 1992;87:355–357.
- 6 Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumor marker CA19-9: clinical interpretation and influence of obstructive jaundice. *Eur J Surg Oncol* 2000;26:474–479.
- 7 Ballehaninna UK, Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. *J Gastrointest Oncol* 2012;3:105–119.

- 8 Murohisa T, Sugaya H, Tetsuka I, Suzuki T, Harada T: A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. *Intern Med* 1992;31:516–520.
- 9 Coleman RE: Clinical PET in oncology. *Clin Positron Imaging* 1998;1:15–30.
- 10 Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. *J Nucl Med* 1992;33:1972–1980.
- 11 Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI: A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. *Am J Gastroenterol* 1999;94:1941–1946.
- 12 Arends JW, Verstynen C, Bosman FT, Hilgers J, Stepelwski Z: Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. *Hybridoma* 1983;2:219–229.
- 13 Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B: The role of ^{18}F -FDG PET/CT in the evaluation of ascites of undetermined origin. *J Nucl Med* 2009;50:506–512.
- 14 Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, Satoh K, Ohkawa M: Dual-time-point ^{18}F -FDG PET for the evaluation of gallbladder carcinoma. *J Nucl Med* 2006;47:633–638.

Fig. 1. Ultrasonography and CT images. **a** Ultrasonography revealing biliary sludge, a gallstone with a diameter of 17 mm, and thickened wall of the gallbladder. **b** Contrast-enhanced CT scan in the coronal view revealing a gallstone in the neck of the gallbladder (white arrow). **c, d** Contrast-enhanced CT scans in horizontal views revealing the enlargement and thickened wall of the gallbladder (white arrow) (**c**) with the gallstone in the neck of gallbladder (white arrow) (**d**).

Fig. 2. ^{18}F -FDG PET-CT images and accumulation of ^{18}F -FDG ($\text{SUV}_{\text{max}}, 9.3$) without tumor shadows in the medial segment of the liver near the fundus of the gallbladder.

Fig. 3. Pathological tissue images. **a** Macroscopically, the gallbladder is edematous and grossly thickened. **b** Pathological examination (HE, ×40) shows that inflammatory cells had spread to all layers of the gallbladder wall. **c, d** On immunostaining examination using CA 19-9 monoclonal antibody, the cytoplasm of the mucosal epithelium was well-stained with CA 19-9 in the gallbladder wall. Low-power (×40) (**c**) and high-power (×400) (**d**) fields.